Navigation Links
Thoratec Announces Presentations at Upcoming Investor Conferences
Date:9/6/2011

PLEASANTON, Calif., Sept. 6, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in three upcoming investor conferences.

On Thursday, September 8, the company will participate in the Robert W. Baird & Co. 2011 Health Care Conference. Taylor Harris, Senior Director of Investor Relations and Business Development, will provide an update on the company beginning at 8:30 a.m., Eastern Daylight Time (5:30 a.m., Pacific Daylight Time). The presentation will be available through the conference web site at http://www.wsw.com/webcast/baird24/thor/, or on the company's web site at http://www.thoratec.com.

On Tuesday, September 13, Thoratec will participate in the Rodman & Renshaw Annual Global Investment Conference. The presentation by Gary F. Burbach, president and chief executive officer, will begin at 9:10 a.m., Eastern Daylight Time (6:10 a.m., Pacific Daylight Time). The presentation will be available through the conference web site at http://www.wsw.com/webcast/rrshq20/thor or on the company's web site at http://www.thoratec.com.

On Wednesday, September 14, Thoratec will participate in the Morgan Stanley Global Healthcare Conference. The presentation by Gary F. Burbach will begin at 8 a.m., Eastern Daylight Time (5 a.m., Pacific Daylight Time), and can be accessed through the conference web site at http://web.servicebureau.net/conf/meta?i=1113299653&c=2343&m=was&u=/w_ccbn.xsl&date_t
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy stores ... opened in Memphis and Cordova ... in Springfield on September 24 and a ... open October 22.  MinuteClinic is the largest and fastest growing provider ... . The Memphis -area clinics join ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
(Date:9/20/2014)... (PRWEB) September 20, 2014 Lifeinsurancequoteterm.net ... advantages a no medical exam life insurance plan provides ... for vulnerable family members should be a top priority ... for life insurance without taking medical examinations and visiting ... not require medical examinations will provide coverage up to ...
(Date:9/20/2014)... 2014 New PharmaPoint Drug Evaluation ... to 2023?. The asthma market saw very slow ... become saturated with relatively efficacious standard therapies, such ... corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, ... However, the launch of seven novel targeted biologic ...
(Date:9/20/2014)... dentists have advised their patients against drinking coffee and wine. ... that advice and changing his stance after considering two recent ... oral health. “There’s good news and great news,” says Dr. ... protecting against gum disease, and red wine can help fight ... the September 2014 issue of Boston University School of ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 QueenBeeTickets.com is ... young star’s tour performances. She will visit many cities ... February until the 16th of April. , Click ... Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s fans ... to see their favorite young singer in a live ...
(Date:9/20/2014)... Everett, WA (PRWEB) September 20, 2014 “Motherhood ... Health Center of Snohomish in their latest article , ... the best that you can—and that’s what we want to ... what services they need and should expect from their Family ... the following days of new motherhood. , To learn ...
Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2
... Educational ... Pain, LAGUNA SECA, Calif., Sept. 25 The Race ... Mike Roman competes,in a Sports Car Club of America racing ... 12 years ago, will race Saturday,September 29th @11:00 a.m. and ...
... Spain: Researchers in Australia have shown that positron ... molecule is more useful than mammography and ultrasound ... and, therefore, the patients ultimate likelihood of survival. ... European Cancer Conference (ECCO 14) in Barcelona, Dr ...
... Researchers have found that the breast cancer susceptibility gene, BRCA1, ... Not only can it be used to predict outcome for ... a valuable tool in choosing the best therapy for them. ... Conference (ECCO 14) in Barcelona, that analysis of the expression ...
... in The Netherlands have developed a method of accurately ... to have their disease recur after surgery and who ... , Led by Professor Rob Tollenaar at Leiden University ... The Netherlands Cancer Institute, they have analysed for the ...
... Case Studies in the Management of PK/PD Data Will be Presented ... ... France, MOUNTAIN VIEW, Calif., Sept. 25 Pharsight,Corporation (OTC ... optimizing clinical drug development, today,announced that Dan Weiner, Ph.D., Senior Vice ...
... 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) ... in,its North American Phase III clinical trial for ... More than 400 patients,have been enrolled in this ... at the end of this week. "Our ...
Cached Medicine News:Health News:Race Against Pain Coming to California 2Health News:Race Against Pain Coming to California 3Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 2Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 3Health News:Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer 2Health News:Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer 3Health News:Molecular profiling can accurately predict survival in colon cancer patients 2Health News:Molecular profiling can accurately predict survival in colon cancer patients 3Health News:Pharsight to Host European Software Conference 2Health News:Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug 2Health News:Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug 3
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Medicine Products: